List A: Advanced therapies covered by your policy – June 2021

New treatments become available all the time and we regularly review them so you can access the latest medical advances. Lists A, B and C are the lists of advanced therapies that are covered by our policies. Advanced therapies fall into three main types: gene therapy medicines, somatic-cell therapy medicines and tissue-engineered medicines. These are defined by the European Medicines Agency and within the UK as Advanced Therapy Medicinal Products (ATMPs).

Please check your membership or trust certificate or guide to find out whether your policy covers List A, List B or List C. If your certificate or guide:
- mentions List A, then List A, which is this list, applies to your policy.
- doesn’t mention either List A, B or C, then List A applies to your policy.
- mentions List B, then List B, which is this list applies to your policy, see List B here www.bupa.co.uk/list-b-advanced-therapies.
- mentions List C, then List C applies to your policy, see List C here www.bupa.co.uk/list-c-advanced-therapies.

As new therapies and medical information become available, we may add or remove them from these lists. You can find more information about when these lists may change in the Changes to Lists section of your membership or trust guide.

You may wish to share this list with your doctor so it’s important that you access the latest version at www.bupa.co.uk/policyinformation

We will only fund advanced therapies that are listed below and are covered by your policy.

Please make sure you call your usual Bupa helpline to authorise any of the advanced therapies listed below before treatment begins. You can find the phone number on your membership or registration certificate or in your guide. We’re open from 8am to 8pm Monday to Friday and 8am to 4pm on Saturdays. We’re here to help.
## List A: Advanced therapies

<table>
<thead>
<tr>
<th>Information for you</th>
<th>Information for your doctor</th>
</tr>
</thead>
<tbody>
<tr>
<td>(i) Generic name</td>
<td>(i) Condition</td>
</tr>
<tr>
<td>(ii) Brand name</td>
<td>(ii) approval required from a multi-disciplinary team</td>
</tr>
<tr>
<td></td>
<td>Bupa authorisation required before treatment begins</td>
</tr>
<tr>
<td>(i) Strength, formulation and pack size</td>
<td>(ii) Marketing authorisation</td>
</tr>
<tr>
<td></td>
<td>When covered by Bupa</td>
</tr>
<tr>
<td></td>
<td>Bupa code</td>
</tr>
</tbody>
</table>

### (i) Talimogene laherparepvec (TVEC)
- **Brand name**: Imlygic
- **Condition**: Cancer only
- **Approval required**: Yes
- **Strength, formulation and pack size**: 10⁶ plaque forming units (PFU)/mL solution for injection
- **Authorisation**: EU/1/15/1064/001
- **When covered by Bupa**: Treatment of adults with unresectable melanoma that is regionally or distantly metastatic (Stage IIIB, IIIC and IVM1a) with no bone, brain, lung or other visceral disease
- **Bupa code**: AD926

### (i) Talimogene laherparepvec (TVEC)
- **Brand name**: Imlygic
- **Condition**: Cancer only
- **Approval required**: Yes
- **Strength, formulation and pack size**: 10⁶ plaque forming units (PFU)/mL solution for injection
- **Authorisation**: EU/1/15/1064/002
- **When covered by Bupa**: Treatment of adults with unresectable melanoma that is regionally or distantly metastatic (Stage IIIB, IIIC and IVM1a) with no bone, brain, lung or other visceral disease
- **Bupa code**: AD927

### (i) INN-tisagenlecleucel
- **Brand name**: Kymriah
- **Condition**: Cancer only AND once approved by the National CAR-T Clinical Panel (NCCP) or an equivalent body or the Bupa CAR-T network
- **Approval required**: Yes
- **Strength, formulation and pack size**: 1.2 x 10⁶ – 6 x 10⁶ cells dispersion for infusion
- **Authorisation**: EU/1/18/1297/001
- **When covered by Bupa**: Paediatric and young adult patients up to 25 years of age with B-cell acute lymphoblastic leukaemia (ALL) that is refractory, in relapse post-transplant or in second or later relapse
- **Bupa code**: AT001
<table>
<thead>
<tr>
<th>Cancer</th>
<th>CAR-T Product</th>
<th>Approval Details</th>
<th>Conditions</th>
<th>Notes</th>
</tr>
</thead>
</table>
| (i) Autologous anti-CD19-transduced CD3+ cells  
(ii) Tecartus | (i) Cancer only AND  
(ii) once approved by the National CAR-T Clinical Panel (NCCP) or an equivalent body or the Bupa CAR-T network hospital Multi-disciplinary team (MDT) | Yes  
(i) 0.4 – 2 × 10⁸ cells dispersion for infusion.  
(ii) PLGB 11972/0045 | Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. | AT003 |
| (i) INN-axicabtagene ciloleucel  
(ii) Yescarta | (i) Cancer only AND  
(ii) once approved by the National CAR-T Clinical Panel (NCCP) or an equivalent body or the Bupa CAR-T network hospital Multi-disciplinary team (MDT) | Yes  
(i) 0.4 – 2 × 10⁸ cells dispersion for infusion  
(ii) EU/1/18/1299/001 | Adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and primary mediastinal large B-cell lymphoma (PMBCL), after two or more lines of systemic therapy. | AT002 |